

Priya B Shete

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2528606/publications.pdf>

Version: 2024-02-01

28
papers

713
citations

759233

12
h-index

580821

25
g-index

35
all docs

35
docs citations

35
times ranked

1129
citing authors

#	ARTICLE	IF	CITATIONS
1	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. <i>Epidemiology</i> , 2022, 33, 75-83.	2.7	2
2	Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. <i>Implementation Science Communications</i> , 2022, 3, 9.	2.2	4
3	State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. <i>PLoS ONE</i> , 2021, 16, e0249012.	2.5	11
4	Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California. <i>Health Affairs</i> , 2021, 40, 870-878.	5.2	102
5	Patient Perspectives and Willingness to Accept Incentives for Tuberculosis Diagnostic Evaluation in Uganda. <i>Value in Health Regional Issues</i> , 2021, 25, 48-56.	1.2	6
6	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 385, 2441-2450.	27.0	13
7	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 356-365.	5.6	13
8	Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020, 18, 100136.	1.3	12
9	Modeling the Impact of Recommendations for Primary Care-Based Screening for Latent Tuberculosis Infection in California. <i>Public Health Reports</i> , 2020, 135, 172S-181S.	2.5	10
10	Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India. <i>Infectious Diseases of Poverty</i> , 2020, 9, 144.	3.7	10
11	Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. <i>Public Health Reports</i> , 2020, 135, 38S-43S.	2.5	2
12	Challenges with scale-up of GeneXpert MTB/RIF [®] in Uganda: a health systems perspective. <i>BMC Health Services Research</i> , 2020, 20, 162.	2.2	23
13	The University of California San Francisco (UCSF) Training Program in Implementation Science: Program Experiences and Outcomes. <i>Frontiers in Public Health</i> , 2020, 8, 94.	2.7	7
14	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). <i>Implementation Science</i> , 2020, 15, 24.	6.9	14
15	Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1639-1642.	3.2	2
16	Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 16, 100110.	1.3	15
17	Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 268.	2.9	48
18	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 15, 100099.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Introducing risk inequality metrics in tuberculosis policy development. Nature Communications, 2019, 10, 2480.	12.8	13
20	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics, 2019, 9, 56.	2.6	2
21	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
22	Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates. PLoS ONE, 2019, 14, e0212617.	2.5	23
23	Outlook for tuberculosis elimination in California: An individual-based stochastic model. PLoS ONE, 2019, 14, e0214532.	2.5	15
24	Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation. BMC Medicine, 2019, 17, 224.	5.5	2
25	Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study. The Lancet Global Health, 2019, 7, e219-e226.	6.3	51
26	Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease. The Lancet Global Health, 2018, 6, e1272-e1273.	6.3	17
27	Measuring success: The challenge of social protection in helping eliminate tuberculosis. PLoS Medicine, 2017, 14, e1002419.	8.4	0
28	Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS ONE, 2017, 12, e0180122.	2.5	27